GTHX - G1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlook May, 01 2024 06:35 AM G1 Therapeutics Inc. 2024-05-01 06:35:23 ET More on G1 Therapeutics Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics GAAP EPS of -$0.21 beats by $0.07, revenue of $14.9M beats by $1.87M Seeking Alpha’s Quant Rating on G1 Therapeutics For further details see: G1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlook